MAPT and Parkinson disease: Tau PET ligands present a similar issue: while 18F-AV-1451 shows extensive off-target binding in PD and multiple system atrophy (MSA), newer tracers like 18F-PI-2620 offer improved specificity for 4R tau, yet their clinical use is limited by issues with standardization and accessibility [159].